Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

21 Feb 2013

Abstract excerpt

Abstract Bromodomain inhibition comprises a promising therapeutic strategy in cancer, particularly for hematologic malignancies. To date, however, genomic biomarkers to direct clinical translation have been lacking. We conducted a cell-based screen of genetically defined cancer cell lines using a prototypical inhibitor of BET bromodomains. Integration of genetic features with chemosensitivity data revealed a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Neuroblastoma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23430699
DOI: 10.1158/2159-8290.cd-12-0418

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting MYCN in Neuroblastoma by BET Bromodomain InhibitionPMID 23430699Read ↗

BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor ModelsSemantic proximity Read ↗

Targeting MYCN-Driven Transcription By BET-Bromodomain InhibitionSemantic proximity Read ↗

Limited antitumor activity of combined BET and MEK inhibition in neuroblastomaSemantic proximity Read ↗

Epigenetic Dysregulation in MYCN-Amplified NeuroblastomaSemantic proximity Read ↗

Molecular targeting therapies for neuroblastoma: Progress and challengesSemantic proximity Read ↗

BET Bromodomain Inhibition of <i>MYC</i> -Amplified MedulloblastomaSemantic proximity Read ↗

Targeting BET Bromodomains in CancerSemantic proximity Read ↗

Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasmsSemantic proximity Read ↗

Targeting BET Bromodomains for Cancer TreatmentSemantic proximity Read ↗

Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System TumorsSemantic proximity Read ↗

Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified NeuroblastomaSemantic proximity Read ↗

Targeting Pathways in Neuroblastoma: Advances in Treatment Strategies and Clinical OutcomesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.